SYMETRYX CORP sold 282.44K shares of NEUBASE THERAPEUTICS, INC. on the open market
Open‑market sale worth $375.6K. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 9/18/2023ACC: 0001991925-23-000005
-282.44K
Net shares
Net seller
$375.6K
Total sold
3
Open market trades
0B · 3S
3
Total transactions
282.44K disposed
Non-Derivative Transactions3
Common Stock, Par Value $0.0001 per Share
Direct
Shares
−129.11K
Price / share
$1.44
Trade value
$185.92K
% of position
45.7%
9/14/2023
282.44K→153.34K
Common Stock, Par Value $0.0001 per Share
Direct
Shares
−103.34K
Price / share
$1.26
Trade value
$130.20K
% of position
67.4%
9/15/2023
153.34K→50K
Common Stock, Par Value $0.0001 per Share
Direct
Shares
−50K
Price / share
$1.19
Trade value
$59.50K
% of position
New position
9/18/2023
50K→0.00
Total
Net shares
−282.44K
Net value
-$375.62K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock, Par Value $0.0001 per Share Direct | 9/14/2023 | S · Sale | −129.11K | $1.44 | $185.92K | 45.7% | 282.44K | 153.34K |
| Common Stock, Par Value $0.0001 per Share Direct | 9/15/2023 | S · Sale | −103.34K | $1.26 | $130.20K | 67.4% | 153.34K | 50K |
| Common Stock, Par Value $0.0001 per Share Direct | 9/18/2023 | S · Sale | −50K | $1.19 | $59.50K | New position | 50K | 0.00 |
| Total | −282.44K | -$375.62K | ||||||
Derivative Transactions0
No derivative transactions reported